Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Huiying Taifu Investment

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 3
Average round size
info
The average size of a deal this fund participated in
$12M
Portfolio companies 2
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Key employees Soon

Areas of investment

  • Consumer Software
  • Consumer
  • Clinical Trials
Summary

The main department of described VC is located in the Beijing. The venture was found in Asia in China.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2018. The fund is constantly included in less than 2 investment rounds annually.

We can highlight the next thriving fund investment areas, such as Consumer, Consumer Software. Among the various public portfolio startups of the fund, we may underline Tiger Sugar For fund there is a match between the location of its establishment and the land of its numerous investments - China.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Huiying Taifu Investment, startups are often financed by Yu Yue, Liao Jing. The meaningful sponsors for the fund in investment in the same round are Yu Yue, Ruishuo Capital, Liao Jing. In the next rounds fund is usually obtained by Ruishuo Capital, Kangchun Capital, Hanwei Capital.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Accelerate St Louis Missouri, St Louis, United States
Actemium Sweden, Vastra Gotaland, Västra Götaland County
Addnode Group Stockholm, Stockholm County, Sweden
Ascension Investment Management Missouri, Saint Louis, United States
Capital Plus Investments Gurgaon, Haryana, India
Corning Technology Ventures Boston, Massachusetts, United States
Dunross & Co -
Extendam -
Groupama Banque France, Ile-de-France, Montreuil
Innovation Warehouse England, London, United Kingdom
Maple Leaf Films -
Miraca Holdings Chiyoda, Japan
Samsung Catalyst Fund California, Menlo Park, United States
SGcapital Japan, Tokyo
Sparklabs Cultiv8 Australia, New South Wales, Orange
Spring Point Partners Pennsylvania, Philadelphia, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Immvira

Clinical Trials
$15M31 Jan 2019 Guangdong Province

Consumer
Consumer Software
$21M29 Oct 2018 Shanghai, China

Consumer
Consumer Software
16 May 2018 Shanghai, China

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Huiying Taifu Investment?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 3
Average round size 12M
Peak activity year 2018
Lead investments 0
Follow on index 0.33
Group Appearance index 0.67

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Immvira

Clinical Trials
$15M31 Jan 2019 Guangdong Province

Consumer
Consumer Software
$21M29 Oct 2018 Shanghai, China

Consumer
Consumer Software
16 May 2018 Shanghai, China
Crunchbase icon

Content report

The following text will be sent to our editors: